Table 4.

Cox regression models showing effect of low molecular weight heparin or heparin (LMWH/heparin) bridging versus no bridging and direct oral anticoagulant (DOAC) versus warfarin on delayed symptomatic intracranial hemorrhage adjusting for potential confounders.

	Analysis 1) LMWH/heparin bridging versus no bridging	Analysis 2) DOAC versus warfarin
Unadjusted	4.47 (1.85 – 10.77), p = 0.001	0.56 (0.22 – 1.42), p = 0.224
Model 1	4.20 (1.73 – 10.18), p = 0.002	0.57 (0.23 – 1.45), p = 0.240
Model 2	3.48 (1.42 – 8.55), p = 0.007	0.48 (0.19 – 1.21), p = 0.119
Model 3	2.74 (1.01 – 7.42), p = 0.047	0.57 (0.22 – 1.48), p = 0.246
Model 4	2.74 (0.90 – 8.34), p = 0.075	0.57 (0.22 – 1.48), p = 0.246

Model 1: adjusted for age and sex, Model 2: adjusted for age, sex, Ischemic lesion > 10, early hemorrhagic transformation, Model 3: age, sex, Ischemic lesion > 10, early hemorrhagic transformation and both predictors (bridging and DOAC treatment), model 4: model 3 + interval to start anticoagulation